AbbVie

January 30, 2020January 30, 2020

Imbruvica Plus Rituximab Prolongs Survival in Untreated CLL/SLL Patients, Phase 3 Trial Finds

News

Imbruvica (ibrutinib) in combination with rituximab continues to prolong survival and the time without disease progression in previously untreated adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ... Read more

January 9, 2020January 15, 2020

Venclexta-rituximab Combo Shows Long-term Survival Benefits for Relapsed CLL Patients

News

A combination of Venclexta (venetoclax) and rituximab continues to significantly reduce the risk of disease progression or death in relapsed or refractory chronic lymphocytic leukemia (CLL) patients two years after completing ... Read more

December 9, 2019December 19, 2019

Imbruvica Extends Time to Disease Worsening over Prior Regimen in MCL, Data Shows

News

The time to disease worsening or death usually shortens with each additional line of therapy, but that does not seem to be the case when the Bruton’s tyrosine kinase (BTK) inhibitor ... Read more

October 31, 2019

Cirmtuzumab-Imbruvica Combo Trial Opens New Expansion Part for Mantle Cell Lymphoma

News

A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people ... Read more

August 27, 2019

Cirmtuzumab-Imbruvica Combo Trial Enrolling CLL, SLL Patients for Phase 2

News

Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of ... Read more

May 28, 2019July 1, 2019

Preclinical Study Uncovers Resistance Mechanisms to Lymphoma Therapy and Potential Way to Overcome Them

News

Lymphoma cells can become resistant to therapy as they acquire novel genetic mutations, but a new study has found that they can also become resistant as they reprogram which genes ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more

January 31, 2019

FDA Approves Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has approved a combination of Imbruvica (ibrutinib) and Gazyva (obinutuzumab) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This is the first ... Read more

January 9, 2019January 31, 2019

First-line Imbruvica-Gazyva Therapy Extends Survival Without Disease Progression in CLL/SLL Patients, Phase 3 Study Shows

News

First-line treatment with Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) significantly extends the time patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) live without cancer progression, and it also increases their ... Read more

October 23, 2018

FDA Grants Priority Review to Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has granted priority review to AbbVie‘s application seeking the approval of Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) for patients with chronic lymphocytic leukemia or small lymphocytic ... Read more